Trial · NCT00107978

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

NCT00107978, Phase 3, Completed, Cumberland Pharmaceuticals; results first posted 2010-02-01

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus. Trials, record NCT00107978. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00107978

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
NCT number: NCT00107978
Status: Completed
Phases: Phase 3
Enrollment: 1,035 participants, actual
Lead sponsor: Cumberland Pharmaceuticals
Conditions: Staphylococcal Skin Infection
Interventions: Telavancin, Vancomycin
First posted: 2005-04-12
Last updated: 2019-01-16
Results first posted: 2010-02-01

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Clinical Response	7 to 14 days after the last antibiotic dose	The Clinical Response for each patient was determined by the investigator by assessing the patient's clinical signs \& symptoms compared with the Baseline evaluation. Cure: resolution of signs and symptoms associated with the skin infection present at study admission such that no further antibiotic therapy was necessary; Not Cured: inadequate response to study therapy; Indeterminate: unable to determine outcome.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Clinical Response	7 to 14 days after the last antibiotic dose	Data for the all-treated population (AT) are presented. The AT and clinically evaluable (CE) populations were considered co-primary.	patients	NUMBER

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Clinical Response	Telavancin	Cure	358	patients
Clinical Response	Vancomycin	Cure	364	patients
Clinical Response	Telavancin	Not cured	59	patients
Clinical Response	Vancomycin	Not cured	57	patients
Clinical Response	Telavancin	Indeterminate	17	patients
Clinical Response	Vancomycin	Indeterminate	20	patients
Clinical Response	Telavancin	Missing	24	patients
Clinical Response	Vancomycin	Missing	40	patients

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Telavancin	458
Overall Study	STARTED	Vancomycin	481
Overall Study	COMPLETED	Telavancin	425
Overall Study	COMPLETED	Vancomycin	431
Overall Study	NOT COMPLETED	Telavancin	33
Overall Study	NOT COMPLETED	Vancomycin	50

Source ClinicalTrials.gov

Adverse events208

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anemia	Blood and lymphatic system disorders	Telavancin	11	503
other	Anemia	Blood and lymphatic system disorders	Vancomycin	10	509
other	Abdominal Pain	Gastrointestinal disorders	Telavancin	6	503
other	Abdominal Pain	Gastrointestinal disorders	Vancomycin	9	509
other	Constipation	Gastrointestinal disorders	Telavancin	35	503
other	Constipation	Gastrointestinal disorders	Vancomycin	24	509
other	Diarrhoea	Gastrointestinal disorders	Telavancin	36	503
other	Diarrhoea	Gastrointestinal disorders	Vancomycin	35	509
other	Dry Mouth	Gastrointestinal disorders	Telavancin	9	503
other	Dry Mouth	Gastrointestinal disorders	Vancomycin	7	509

1 to 10 of 208Source ClinicalTrials.gov

See all 208 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Telavancin
Total, all-cause mortality	Vancomycin
Total, other adverse events	Telavancin	377	503
Total, other adverse events	Vancomycin	341	509
Total, serious adverse events	Telavancin	38	503
Total, serious adverse events	Vancomycin	15	509

Source ClinicalTrials.gov

Papers3

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
18444791	RESULT	PubMed
19095213	RESULT	PubMed
22416054	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Telavancin vs Vancomycin: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00107978

GET https://conductscience.org/api/trials/v1/NCT00107978/events?page=2

API reference For AI assistants